 Home > Active Ingredient News > Antitumor Therapy > JCO: Clinicopathological characteristics of NRG1 fusion-positive lung cancer and its response to various treatments

JCO: Clinicopathological characteristics of NRG1 fusion-positive lung cancer and its response to various treatments

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

global 2

1 5 whiskey

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Although NRG1 gene fusion is a carcinogenic driving factor for many types of tumors, including lung cancer, it is difficult to study because it is relatively rare

NRG1 gene fusion is a carcinogenic driver of many types of tumors including lung cancer

From June 2018 to February 2020, a consortium of 22 centers from 9 countries in Europe, subgroups, and the United States provided pathologically verified data on lung cancer patients carrying NRG1 gene fusion, including DNA and or RNA-based second-generation sequencing data and fluorescence in situ hybridization

management

A total of 110 patients with NRG1 fusion-positive lung cancer were included .

110 cases of lung cancer patients with NRG1 fusion positive

Research Process

RNA-based testing identified the majority of fusions (74%)

NRG1 fusion-positive lung cancer patients treated with platinum-containing dual-drug and paclitaxel-based chemotherapy (after platinum dual-drug therapy) had lower objective response rates (ORRs were 13% and 14%, respectively), and median progression-free survival The period is average (PFS is 5.

NRG1 fusion-positive lung cancer patients treated with platinum-containing dual-drug and paclitaxel-based chemotherapy (after platinum dual-drug therapy) have a low objective response rate and median progression-free survival.

Prognosis of patients treated with trastuzumab

Consistent with the immunophenotype of low PD-L1 expression (28%) and low tumor mutation burden (median 0.

Immunization with chemotherapy-immunotherapy and monoimmunotherapy is less active

All in all, NRG1 gene fusion-positive lung cancer is more heterogeneous molecularly, pathologically and clinically than previously recognized

NRG1 gene fusion-positive lung cancer is more heterogeneous than previously recognized molecularly, pathologically and clinically

Original source:

Drilon Alexander,Duruisseaux Michael,Han Ji-Youn et al.

NRG1Clinicopathologic Features and Response to Therapy of Fusion -Driven Lung Cancers: The eNRGy1 Global Multicenter Registry

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.